CLINICAL ACTIVITY AND PHARMACOKINETICS (PK) OF CABOZANTINIB (XL184) IN PATIENTS WITH PROGRESSIVE MEDULLARY THYROID CARCINOMA (MTC)

被引：0
|
作者：
Cohen, E. E. W. [1 ]
Elisei, R. [2 ]
Schlumberger, M. J. [3 ]
Mueller, S. P. [4 ]
Schoeffski, P. [5 ]
Brose, M. [6 ]
Shah, M. [7 ]
Miles, D. R. [8 ]
Nguyen, L. T. [8 ]
Sherman, S. [9 ]
机构：
[1] Univ Chicago, Med Ctr, Dept Med, Chicago, IL 60637 USA
[2] Univ Pisa, Dept Endocrinol, Pisa, Italy
[3] Inst Canc Res, Villejuif, France
[4] Univ Klinikum Essen, Klin & Poliklin Nukl Med, Essen, Germany
[5] Univ Hosp Leuven, Dept Gen Med Oncol, Louvain, Belgium
[6] Univ Penn Hlth Syst, Dept Med, Philadelphia, PA USA
[7] Ohio State Univ, Coll Med, Columbus, OH 43210 USA
[8] Exelixis Inc, Nonclin Dev, San Francisco, CA USA
[9] Univ Texas MD Anderson Canc Ctr, Dept Endocrine Neoplasia & Hormonal Disord, Houston, TX 77030 USA
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：154 / 155
页数：2
相关论文
共 50 条
  • [31] A phase II study of XL184 in patients (pts) with progressive glioblastoma multiforme (GBM) in first or second relapse
    De Groot, J. F.
    Prados, M.
    Urquhart, T.
    Robertson, S.
    Yaron, Y.
    Sorensen, A. G.
    Norton, A.
    Batchelor, T.
    Drappatz, J.
    Wen, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [32] A dose finding clinical trial of cabozantinib (XL184) administered in combination with abiraterone acetate in metastatic castration-resistant prostate cancer
    Choudhury, Atish D.
    Gray, Kathryn P.
    Supko, Jeffrey G.
    Harshman, Lauren C.
    Taplin, Mary-Ellen
    Pace, Amanda F.
    Farina, Matthew
    Zukotynski, Katherine A.
    Bernard, Brandon
    Kantoff, Philip W.
    Pomerantz, Mark
    Sweeney, Christopher
    PROSTATE, 2018, 78 (14): : 1053 - 1062
  • [33] Activity of cabozantinib (XL184) in soft tissue and bone: Results of a phase II randomized discontinuation trial (RDT) in patients (pts) with advanced solid tumors.
    Gordon, M. S.
    Vogelzang, N. J.
    Schoffski, P.
    Daud, A.
    Spira, A. I.
    O'Keeffe, B. A.
    Rafferty, T.
    Lee, Y.
    Berger, R.
    Shapiro, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [34] Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma
    Schlumberger, M.
    Elisei, R.
    Mueller, S.
    Schoffski, P.
    Brose, M.
    Shah, M.
    Licitra, L.
    Krajewska, J.
    Kreissl, M. C.
    Niederle, B.
    Cohen, E. E. W.
    Wirth, L.
    Ali, H.
    Clary, D. O.
    Yaron, Y.
    Mangeshkar, M.
    Ball, D.
    Nelkin, B.
    Sherman, S.
    ANNALS OF ONCOLOGY, 2017, 28 (11) : 2813 - 2819
  • [35] A phase I dose-escalation study of the safety and pharmacokinetics (PK) of XL184, a VEGFR and MET kinase inhibitor, administered orally to patients (pts) with advanced malignancies
    Salgia, R.
    Hong, D. S.
    Camacho, L. H.
    Ng, C. S.
    Janisch, L.
    Ratain, M. J.
    Kurzrock, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [36] Intronic changes in our patients with Medullary Thyroid Carcinoma (MTC)
    Bergant, D. M.
    Glavac, D.
    Glumac, N.
    Peric, B.
    Hocevar, M.
    WIENER KLINISCHE WOCHENSCHRIFT, 2014, 126 : S144 - S144
  • [37] PHASE 1 DOSE ESCALATION TRIAL OF THE SAFETY AND PHARMACOKINETICS (PK) OF CABOZANTINIB (XL184) CONCURRENT WITH TEMOZOLOMIDE (TMZ) & RADIATION (RT) OR TMZ POST-RT IN NEWLY DIAGNOSED HIGH-GRADE GLIOMAS (HGG)
    Schiff, David
    Desjardins, Annick
    Cloughesy, Timothy
    Mikkelsen, Tom
    Glantz, Michael
    Chamberlain, Marc
    Reardon, David A.
    Wen, Patrick
    NEURO-ONCOLOGY, 2013, 15 : 81 - 81
  • [38] Phase 2 study of XL184 (BMS-907351) in a cohort of patients (pts) with hepatocellular carcinoma (HCC)
    Van Cutsem, E.
    Su, W. C.
    Davis, J.
    Haas, N.
    Samuel, T. A.
    Tsao, C. J.
    Yang, T. S.
    Brandy, H.
    Mann, G.
    Cohn, A.
    EJC SUPPLEMENTS, 2010, 8 (07): : 129 - 130
  • [39] A phase 1 dose-escalation study of the safety and pharmacokinetics (PK) of XL184, a VEGFR and MET kinase inhibitor, administered orally to patients (pts) with advanced malignancies.
    Salgia, Ravi
    Hong, David
    Sherman, Steven I.
    Ng, Chann
    Frye, John
    Janish, Linda
    Ratain, Mark
    Kurzrock, Razelle
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3385S - 3385S
  • [40] MOLECULAR PROFILE AND ANTI-TUMOR ACTIVITY IN NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS (PTS) IN A PHASE 1 STUDY OF CABOZANTINIB (XL184) IN JAPAN
    Nokihara, H.
    Yamamoto, N.
    Nakamichi, S.
    Wakui, H.
    Yamada, Y.
    Frye, J.
    Decillis, A.
    Tamura, T.
    ANNALS OF ONCOLOGY, 2012, 23 : 174 - 174
12345